May Health is a medical device company focused on expanding therapeutic options for women suffering from polycystic ovary syndrome (PCOS)-related infertility. Its lead product, the Anavi™ System, enables a one-time, office-based procedure intended to restore ovulation in patients who do not respond to, are contraindicated to, or decline first-line treatments. The device secured CE Mark certification under EU MDR in October 2025 and is currently being evaluated in the U.S. REBALANCE pivotal IDE trial across more than 15 fertility centers. By targeting a condition that affects an estimated 10–13% of reproductive-age women worldwide, the company addresses a significant unmet clinical need. Management is advancing toward FDA marketing authorization while simultaneously preparing for commercialization in Europe and the United States. Backed by a syndicate of life-science investors, May Health is capitalizing on strategic partnerships to accelerate clinical development and future market launch.

Total raised

$48M

Funding rounds

3

Latest round

Equity

Latest activity

Mar 2026